ASCO25: Roche's Itovebi combo reduces risk of death in breast cancer by 33%
Roche's blockbuster vision for phosphoinositide 3-kinase (PI3K inhibitor) Itovebi (inavolisib) has been dealt a boost after the drug demonstrated further positive overall survival (OS) data in a common subtype of breast cancer.
In combination with Pfizer's CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi reduced the risk of death by 33% in patients with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer that has grown during or after hormone therapy treatment.
The new OS results came from the Phase III INAVO120 study (NCT05646862) evaluating the triple therapy compared to Ibrance and Faslodex alone. Roche published an abstract containing the data ahead of a presentation at the American Society of Clinical Oncology (ASCO) 2025 meeting taking place from 30 May to 3 June in Chicago, Illinois.
Itovebi won US Food and Drug Administration (FDA) approval in this breast cancer indication based on INAVO120's data late last year, although full analysis of the OS has only been completed by Roche now.
The study, which enrolled 325 patients, saw Roche's Itovebi combination led to a median OS of 34 months compared to 27 months for those who took a placebo along with Ibrance and Faslodex. The median follow-up was just under three years.
The results consolidate previous data that showed adding Itovebi to the treatment regimen more than doubled progression-free survival (PFS) to 15 months. With the full analysis now available, Roche has updated this to 17.2 months, compared to the 7.3 months in the comparator arm.
Coupled with the OS data, the results are a landmark moment in the P13KCA landscape. No other pharma company has developed a candidate that reaches the 33% Itovebi has achieved. For example, rival PI3K inhibitor Piqray developed by Novartis, failed to produce a statistically significant difference in OS in breast cancer patients with a PIK3CA mutation. Piqray is FDA-approved as a second-line therapy option, whereas Itovebi is a first-line treatment.
HR-positive, HER2-negative breast cancer is the most common subtype of breast cancer. About 40% of these patients have a mutation in the PIK3CA gene.
PI3K inhibitors have long been troubled by safety concerns. Roche's Itovebi is no different, with 90.7% of patients experiencing Grade 3 or 4 adverse events (AEs). However, a high rate was also seen in the placebo/Ibrance/Faslodex arm – 84.7%. Hyperglycaemia was an AE singled out in the analysis, being particularly prevalent in the Itovebi group at 63.4%, versus 13.5% in the other arm.
Backed by previous survival data, Roche has high hopes for Itovebi, forecasting peak sales of $2.3bn. Analysis by GlobalData, which goes up to 2031, has forecast peak sales of $1.4bn.
GlobalData is the parent company of Pharmaceutical Technology and Clinical Trials Arena.
'The INAVO120 trial has identified a targeted treatment regimen that meaningfully improves survival in patients with untreated PIK3CA-mutated hormone receptor-positive metastatic breast cancer – a big step forward for these patients,' said Jane Lowe Meisel, co-director of Breast Medical Oncology at the Winship Cancer Institute of Emory University School of Medicine, and an ASCO Expert in breast cancer.
"This study illustrates the importance of genomic testing at the time of diagnosis of hormone receptor-positive metastatic breast cancer so that patients with PIK3CA mutations who qualify for this approach can be readily identified.'
"ASCO25: Roche's Itovebi combo reduces risk of death in breast cancer by 33%" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Breakthrough in search for HIV cure leaves researchers ‘overwhelmed'
A cure for HIV could be a step closer after researchers found a new way to force the virus out of hiding inside human cells. The virus's ability to conceal itself inside certain white blood cells has been one of the main challenges for scientists looking for a cure. It means there is a reservoir of the HIV in the body, capable of reactivation, that neither the immune system nor drugs can tackle. Now researchers from the Peter Doherty Institute for Infection and Immunity in Melbourne, have demonstrated a way to make the virus visible, paving the way to fully clear it from the body. It is based on mRNA technology, which came to prominence during the Covid-19 pandemic when it was used in vaccines made by Moderna and Pfizer/BioNTech. In a paper published in Nature Communications, the researchers have shown for the first time that mRNA can be delivered into the cells where HIV is hiding, by encasing it in a tiny, specially formulated fat bubble. The mRNA then instructs the cells to reveal the virus. Globally, there are almost 40 million people living with HIV, who must take medication for the rest of their lives in order to suppress the virus and ensure they do not develop symptoms or transmit it. For many it remains deadly, with UNAids figures suggesting one person died of HIV every minute in 2023. It was 'previously thought impossible' to deliver mRNA to the type of white blood cell that is home to HIV, said Dr Paula Cevaal, research fellow at the Doherty Institute and co-first author of the study, because those cells did not take up the fat bubbles, or lipid nanoparticles (LNPs), used to carry it. The team have developed a new type of LNP that those cells will accept, known as LNP X. She said: 'Our hope is that this new nanoparticle design could be a new pathway to an HIV cure.' When a colleague first presented test results at the lab's weekly meeting, Cevaal said, they seemed too good to be true. 'We sent her back into the lab to repeat it, and she came back the next week with results that were equally good. So we had to believe it. And of course, since then, we've repeated it many, many, many more times. 'We were overwhelmed by how [much of a] night and day difference it was – from not working before, and then all of a sudden it was working. And all of us were just sitting gasping like, 'wow'.' Further research will be needed to determine whether revealing the virus is enough to allow the body's immune system to deal with it, or whether the technology will need to be combined with other therapies to eliminate HIV from the body. The study is laboratory based and was carried out in cells donated by HIV patients. The path to using the technology as part of a cure for patients is long, and would require successful tests in animals followed by safety trials in humans, likely to take years, before efficacy trials could even begin. 'In the field of biomedicine, many things eventually don't make it into the clinic – that is the unfortunate truth; I don't want to paint a prettier picture than what is the reality,' stressed Cevaal. 'But in terms of specifically the field of HIV cure, we have never seen anything close to as good as what we are seeing, in terms of how well we are able to reveal this virus. 'So from that point of view, we're very hopeful that we are also able to see this type of response in an animal, and that we could eventually do this in humans.' Dr Michael Roche of the University of Melbourne and co-senior author of the research, said the discovery could have broader implications beyond HIV, with the relevant white blood cells also involved in other diseases including cancers. Dr Jonathan Stoye, a retrovirologist and emeritus scientist at the Francis Crick Institute, who was not involved in the study, said the approach taken by the Melbourne team appeared be a major advance on existing strategies to force the virus out of hiding, but further studies would be needed to determine how best to kill it after that. He added: 'Ultimately, one big unknown remains. Do you need to eliminate the entire reservoir for success or just the major part? If just 10% of the latent reservoir survives will that be sufficient to seed new infection? Only time will tell. 'However, that does not detract from the significance of the current study, which represents a major potential advance in delivery of mRNA for therapeutic purposes to blood cells.' Prof Tomáš Hanke of the Jenner Institute, University of Oxford, disputed the idea that getting RNA into white blood cells had been a significant challenge. He said the hope that all cells in the body where HIV was hiding could be reached in this way was 'merely a dream'.
Yahoo
an hour ago
- Yahoo
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
President Donald Trump's tariff-induced stock swoon rolled out the red carpet for investors to snag high-quality stocks at a discount. Buying stocks and holding those positions for multiple years is ingrained into my investment philosophy. High-yield dividend stocks, a deeply-discounted legal monopoly, a uniquely-positioned growth stock, and a handful of turnaround candidates were on my buy list through May. 10 stocks we like better than Pfizer › It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all-time record-closing high. But over the next two months, tariff-related uncertainty pushed the Nasdaq Composite into its first bear market in three years, and weighed the S&P 500 down to near-bear market territory. Historically, double-digit percentage declines in the major stock indexes represent ideal opportunities for long-term investors to pounce. As of this writing on June 2, I hold 38 positions in my portfolio -- 37 stocks and one exchange-traded fund (ETF) -- and only four of these stakes have been held for less than a year. Buying and holding stocks for years is ingrained into my investment philosophy. With volatility begetting opportunity, here are all six stocks I've bought through the first five months of 2025. One of the new holdings I added to my portfolio this year is pharmaceutical titan Pfizer (NYSE: PFE). The two separate purchases I've made gave me a cost basis of $23.47 per share, which is a penny above where shares closed on June 2. What makes Pfizer so attractive is that it's been punished for its own success. After generating north of $56 billion in combined sales for its COVID-19 vaccine (Comirnaty) and oral therapy (Paxlovid) in 2022, combined sales tumbled to around $11 billion in 2024. But even if these sales fall again in 2025, Pfizer has, collectively, grown its net product revenue by more than 50% over four years. The shortsightedness of select investors is creating a significant buying opportunity for long-term-minded investors. Additionally, Pfizer's oncology segment can be a key growth driver in the years to come. It completed a $43 billion acquisition of cancer-drug developer Seagen in December 2023. This deal added more than $3 billion in immediate sales to Pfizer's oncology portfolio, as well as vastly expanded its pipeline. With Pfizer also targeting billions of dollars in annual cost-savings, a forward price-to-earnings (P/E) ratio of less than 8, coupled with a dividend yield of more than 7%, was too enticing to pass up. The stock I've unquestionably put the most money to work in this year is adtech company PubMatic (NASDAQ: PUBM). I've more than doubled my stake in the company since late February, with a cost basis from shares purchased this year of $9.29. PubMatic is perfectly positioned to take advantage of businesses shifting their ad dollars from print and billboards to digital channels, such as video, mobile, and connected TV (i.e., streaming content). PubMatic's cloud-based programmatic ad platform assists publishers in selling their digital display space. Aside from digital advertising offering sustained double-digit sales growth, PubMatic will benefit from its decision to build out its cloud infrastructure platform. Though it would have been easier to rely on a third party, taking the time to build out this critical infrastructure will now allow PubMatic to hang onto more of its revenue as it scales. This should lead to superior margins, relative to other sell-side providers. Furthermore, PubMatic is swimming with cash. It's been generating positive operating cash flow for a decade and has been aggressively repurchasing its own stock. When backing out its cash position, investors are paying less than $9 per share for a company fully capable of producing more than $1 in earnings per share in a thriving economy. Although the stock market is historically pricey, select value stocks can be found. Satellite-radio operator Sirius XM Holdings (NASDAQ: SIRI) certainly fits the bill. The one add I made to my existing Sirius XM stake came at $19.28 per share on April 4. The great thing about Sirius XM is that it's a legal monopoly. Even though it's still fighting for listeners with traditional radio companies, being the only licensed satellite-radio operator does afford the company some degree of subscription pricing power. Even more important, Sirius XM generates the bulk of its revenue differently than terrestrial and online radio companies. Whereas the latter are heavily reliant on advertising, Sirius XM generates a little over three-quarters of its net sales from subscriptions. When recessions do occur, subscribers are far less likely to cancel their service than businesses are to meaningfully pare back their ad spending. On paper, this makes Sirius XM's operating cash flow far more predictable. Sirius XM's forward P/E of 7, when combined with a dividend yield that's currently above 5%, makes for a tantalizing buy. Semiconductor behemoth Intel (NASDAQ: INTC) is another long-term holding that I chose to add to during President Donald Trump's tariff-induced market swoon. The lone addition was made on April 8 at $18.56. My wager on Intel is that management can eventually turn around a business that was late to the artificial intelligence (AI) party. While Intel's graphics processing units (GPUs) haven't exactly flown off the shelves like Nvidia's hardware, AI is a massive enough addressable market that even latecomers with established brand names can thrive. Despite its GPU tardiness, Intel's central processing units (CPUs) continue to play a key role in high-compute data centers and traditional desktops/laptops. Even with Advanced Micro Devices chipping away at Intel's once monopoly like CPU market share, Intel remains the decisive leader. The robust cash flow generated from its CPU sales can help Intel redirect capital to higher-growth initiatives. While trading in the mid-$18s, Intel stock was also nearing its tangible book value and had fallen 19% below its listed book value, as of the most recent quarter. Though book value is just one of many valuation measures, I believe there are enough levers to pull and long-term catalysts for Intel stock to bounce back. Specialty drugmaker BioMarin Pharmaceutical (NASDAQ: BMRN) is another holding I've purchased for the first time in 2025. My lone purchase occurred on April 8 at a cost basis of $56.01. One of the variables that makes BioMarin such an attractive investment is its focus on ultrarare diseases. Though the clinical success rate in treating rare diseases can be dicey, positive clinical trials can lead to approved therapies that face little or no competition. What's more, insurers rarely push back on high list prices for rare-disease drugs that have no alternatives. BioMarin's shining star for the moment is Voxzogo, a drug used to treat achondroplasia, which is a common type of dwarfism. A combination of strong pricing power and label expansion opportunities should lead to Voxzogo eventually topping $1 billion in annual sales. Further, BioMarin is targeting $4 billion in annual sales by 2027, which would be up from $2.85 billion in reported sales for 2024. Given the exceptionally high margins associated with ultrarare-disease drugs, BioMarin's forward P/E of 10.6, and its projected low-double-digit sales growth rate, make its stock quite the bargain. Last but not least, I added to my existing position in edge cloud-computing company Fastly (NYSE: FSLY) during the Trump tariff tumble. The only addition came on April 4 at a cost of $5.08 per share. Similar to Intel, Fastly is a work in progress that isn't going to right itself overnight. The investment thesis here is that as businesses shift their data and that of their customers online and into the cloud, demand for rapid and secure content delivery network (CDN) services will only increase. Fastly aggressively expanded the capabilities of its CDN following the pandemic. Although not all of Fastly's key performance indicators (KPIs) have moved in the right direction, some of the most important KPIs suggest management is making the right moves. For instance, its revenue retention rate is locked in at 99% or higher, and its enterprise customer count, while a bit volatile, has been chopping its way higher. Perhaps the most exciting number in Fastly's latest quarter is its remaining performance obligation (i.e., its backlog), which surged above $300 million. Considering that Fastly is generating positive operating cash flow, the foundation for future profits has been laid. Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Sean Williams has positions in BioMarin Pharmaceutical, Fastly, Intel, Pfizer, PubMatic, and Sirius XM. The Motley Fool has positions in and recommends Advanced Micro Devices, Fastly, Intel, Nvidia, Pfizer, and PubMatic. The Motley Fool recommends BioMarin Pharmaceutical and recommends the following options: short August 2025 $24 calls on Intel. The Motley Fool has a disclosure policy. Here Are All 6 Stocks I've Bought Through 5 Months of 2025 was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
UK Stocks Trading Up To 43.9% Below Intrinsic Value Estimates
The United Kingdom's FTSE 100 index has recently faced downward pressure, influenced by weak trade data from China, a key trading partner, highlighting the interconnectedness of global markets. Despite these challenges, opportunities may arise for investors seeking undervalued stocks that are trading below their intrinsic value estimates. In such uncertain times, identifying stocks with strong fundamentals and potential for growth can be crucial for navigating market volatility effectively. Name Current Price Fair Value (Est) Discount (Est) Victrex (LSE:VCT) £7.99 £15.61 48.8% Velocity Composites (AIM:VEL) £0.27 £0.49 44.9% SDI Group (AIM:SDI) £0.715 £1.34 46.8% Just Group (LSE:JUST) £1.486 £2.95 49.7% Informa (LSE:INF) £8.008 £14.47 44.7% Huddled Group (AIM:HUD) £0.0335 £0.06 44% GlobalData (AIM:DATA) £1.74 £3.10 43.9% Entain (LSE:ENT) £7.504 £13.70 45.2% Duke Capital (AIM:DUKE) £0.2875 £0.53 46.1% Deliveroo (LSE:ROO) £1.757 £3.13 43.8% Click here to see the full list of 51 stocks from our Undervalued UK Stocks Based On Cash Flows screener. Let's uncover some gems from our specialized screener. Overview: GlobalData Plc, along with its subsidiaries, offers business information through proprietary data, analytics, and insights across Europe, North America, and the Asia Pacific regions with a market cap of £1.32 billion. Operations: The company's revenue segments include £109.40 million from Data, Analytics and Insights in Healthcare and £176.10 million from Non-Healthcare sectors. Estimated Discount To Fair Value: 43.9% GlobalData is trading at £1.74, significantly below its estimated fair value of £3.10, indicating potential undervaluation based on discounted cash flow analysis. Earnings are projected to grow 23.68% annually over the next three years, outpacing both revenue growth and the broader UK market's earnings growth rate. Despite recent acquisition interest from KKR being terminated due to unmet terms, discussions with ICG continue, potentially impacting future valuations and strategic direction. In light of our recent growth report, it seems possible that GlobalData's financial performance will exceed current levels. Unlock comprehensive insights into our analysis of GlobalData stock in this financial health report. Overview: Kainos Group plc provides digital technology services across the United Kingdom, Ireland, North America, Central Europe, and internationally with a market capitalization of £893.02 million. Operations: Kainos Group's revenue is primarily derived from three segments: Digital Services (£197.17 million), Workday Products (£71.35 million), and Workday Services (£98.72 million). Estimated Discount To Fair Value: 12.1% Kainos Group is trading at £7.31, slightly below its estimated fair value of £8.31, suggesting some undervaluation based on cash flows. The company's earnings are forecast to grow 16.9% annually, surpassing the UK market's growth rate of 14.5%. Despite a recent decline in sales and net income for the year ended March 2025, Kainos announced a £30 million share buyback program to reduce share capital and proposed a final dividend of 19.1p per share pending shareholder approval. The analysis detailed in our Kainos Group growth report hints at robust future financial performance. Take a closer look at Kainos Group's balance sheet health here in our report. Overview: Playtech plc is a technology company that provides gambling software, services, content, and platform technologies across various regions including Italy, Mexico, the UK, Europe, Latin America, and internationally with a market cap of approximately £945.60 million. Operations: Playtech's revenue is derived from segments including Gaming B2B (€754.30 million) and B2C operations such as HAPPYBET (€18.90 million) and Sun Bingo along with other B2C activities (€78.90 million). Estimated Discount To Fair Value: 15.8% Playtech, trading at £3.08, is undervalued based on cash flows with a fair value estimate of £3.65. Despite recent volatility and a net loss of €23.9 million in 2024, earnings are expected to grow significantly by 69.29% annually and become profitable within three years. The company recently completed the sale of Snaitech, enabling it to redeem €150 million in debt and announce a substantial special dividend funded by the sale proceeds. Our earnings growth report unveils the potential for significant increases in Playtech's future results. Click here and access our complete balance sheet health report to understand the dynamics of Playtech. Click here to access our complete index of 51 Undervalued UK Stocks Based On Cash Flows. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AIM:DATA LSE:KNOS and LSE:PTEC. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
